Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Escitalopram Oxalate Tablets 20 mg Clear all

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets 20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Treatment Outcome
Interventions: Vortioxetine, Escitalopram, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Major Depressive Disorder, Insomnia
Interventions: Escitalopram, Ramelteon, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Healthy Control; Drug · Other
Lead sponsor: Wyss Institute at Harvard University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI); Drug · Other · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets (20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Major Depressive Disorder
Interventions: AZD7268, Escitalopram, Placebo capsules, Placebo tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more

Conditions: Major Depressive Disorder
Interventions: Pexacerfont, Escitalopram, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 45
States / cities: Springdale, Arkansas • Orange, California • Upland, California + 39 more

Conditions: PMS
Interventions: escitalopram, placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression
Interventions: citalopram and escitalopram; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypercapnia, Ventilatory Depression
Interventions: Placebo and Oxycodone, Paroxetine and Oxycodone, Escitalopram and Oxycodone; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, Escitalopram; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions: Placebo, Escitalopram; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Myocardial Ischemia
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg

Aripiprazole and Lexapro Drug Interaction Study

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

Exploring Biomarkers for Depression

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

AZD7268 Safety and Tolerability Study

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Study for Participants With Major Depression

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Responses of Myocardial Ischemia to Escitalopram Treatment